Open Orphan PLC - pharmaceutical services provider - Says its subsidiary hVIVO Services Ltd signed a GBP5 million contract with a biotech company that is currently developing an antiviral drug for protection against respiratory viral infections. Specifies that the contract is for an Influenza human challenge study that is expected to commence in the second half of 2022. Explains that it will test and assess the efficacy of a single dosing regimen of the biotech company's antiviral drug. Adds that the study will be conducted with healthy adult volunteers and using hVIVO's Influenza human challenge study model.
"We have now signed contracts for 95% of our 2022 forecasted revenue. This is the fourth Influenza human challenge study that we have signed in 2021 and coupled with the contract wins that we have seen in other disease areas, this further underlines the growing interest in respiratory and infectious diseases within the pharmaceutical and biotechnology industries, which we expect to continue over the coming years," Chief Executive Cathal Friel commented.
Current stock price: 22.86 pence, up 8.2% on Tuesday
Year-to-date change: down 0.9%
By Abby Amoakuh; abbyamoakuh@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.